Conavi Medical Announces Uplisting to OTCQB Venture Market
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) has received approval for uplisting from the OTC Pink Open Market to the OTCQB Venture Market, with trading scheduled to begin on March 6, 2025. The company will maintain its ticker symbol CNVIF, and no shareholder action is required.
The OTCQB listing, which complements Conavi's TSX Venture Exchange presence, is expected to enhance visibility and access to U.S. investors. The move coincides with the company's preparations for the commercial launch of their next-generation Novasight system.
The OTCQB Venture Market, operated by OTC Markets Group, is recognized by the SEC as an established public market for securities registration purposes. Listed companies must maintain current reporting status and undergo annual verification processes.
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) ha ricevuto l'approvazione per il passaggio dall'OTC Pink Open Market al OTCQB Venture Market, con l'inizio delle contrattazioni previsto per il 6 marzo 2025. L'azienda manterrà il suo simbolo di ticker CNVIF e non è richiesta alcuna azione da parte degli azionisti.
La quotazione OTCQB, che si aggiunge alla presenza di Conavi nel TSX Venture Exchange, dovrebbe migliorare la visibilità e l'accesso agli investitori statunitensi. Questa mossa coincide con i preparativi dell'azienda per il lancio commerciale del loro sistema di nuova generazione Novasight.
Il OTCQB Venture Market, gestito da OTC Markets Group, è riconosciuto dalla SEC come un mercato pubblico consolidato per fini di registrazione dei titoli. Le aziende quotate devono mantenere uno stato di reporting aggiornato e sottoporsi a processi di verifica annuali.
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) ha recibido la aprobación para pasar del OTC Pink Open Market al OTCQB Venture Market, con el inicio de las operaciones programado para el 6 de marzo de 2025. La empresa mantendrá su símbolo de ticker CNVIF y no se requiere ninguna acción por parte de los accionistas.
La cotización en el OTCQB, que complementa la presencia de Conavi en el TSX Venture Exchange, se espera que mejore la visibilidad y el acceso a inversores estadounidenses. Este movimiento coincide con los preparativos de la empresa para el lanzamiento comercial de su sistema de nueva generación Novasight.
El OTCQB Venture Market, operado por OTC Markets Group, es reconocido por la SEC como un mercado público establecido para fines de registro de valores. Las empresas listadas deben mantener un estado de reporte actualizado y someterse a procesos de verificación anuales.
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF)는 OTC Pink Open Market에서 OTCQB Venture Market으로의 상장 승인을 받았으며, 거래는 2025년 3월 6일에 시작될 예정입니다. 회사는 티커 기호 CNVIF를 유지하며, 주주 행동은 필요하지 않습니다.
OTCQB 상장은 Conavi의 TSX Venture Exchange 존재를 보완하며, 미국 투자자에 대한 가시성과 접근성을 향상시킬 것으로 기대됩니다. 이 조치는 회사의 차세대 Novasight 시스템 상용 출시 준비와 일치합니다.
OTCQB Venture Market은 OTC Markets Group에서 운영하며, SEC에 의해 증권 등록 목적으로 인정된 확립된 공공 시장입니다. 상장된 회사는 현재 보고 상태를 유지하고 연례 검증 절차를 거쳐야 합니다.
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) a reçu l'approbation pour passer de l'OTC Pink Open Market au OTCQB Venture Market, avec le début des échanges prévu pour le 6 mars 2025. L'entreprise conservera son symbole boursier CNVIF, et aucune action des actionnaires n'est requise.
La cotation OTCQB, qui complète la présence de Conavi sur le TSX Venture Exchange, devrait améliorer la visibilité et l'accès aux investisseurs américains. Ce mouvement coïncide avec les préparatifs de l'entreprise pour le lancement commercial de leur système de nouvelle génération Novasight.
Le OTCQB Venture Market, géré par OTC Markets Group, est reconnu par la SEC comme un marché public établi à des fins d'enregistrement de titres. Les entreprises cotées doivent maintenir un statut de reporting à jour et subir des processus de vérification annuels.
Conavi Medical (TSXV: CNVI; OTCQB: CNVIF) hat die Genehmigung für den Wechsel vom OTC Pink Open Market zum OTCQB Venture Market erhalten, wobei der Handel am 6. März 2025 beginnen soll. Das Unternehmen wird sein Tickersymbol CNVIF beibehalten, und es sind keine Maßnahmen der Aktionäre erforderlich.
Die OTCQB-Notierung, die die Präsenz von Conavi an der TSX Venture Exchange ergänzt, wird voraussichtlich die Sichtbarkeit und den Zugang für US-Investoren verbessern. Dieser Schritt fällt mit den Vorbereitungen des Unternehmens für den kommerziellen Start ihres nächsten Novasight-Systems zusammen.
Der OTCQB Venture Market, der von der OTC Markets Group betrieben wird, wird von der SEC als etablierter öffentlicher Markt für die Registrierung von Wertpapieren anerkannt. Gelistete Unternehmen müssen den aktuellen Berichtsstatus aufrechterhalten und jährliche Verifizierungsprozesse durchlaufen.
- Uplisting to OTCQB from Pink Open Market
- Increased access to U.S. investor base
- Upcoming launch of next-generation Novasight system
- Maintains dual listing with TSX Venture Exchange
- None.
- Expected to enhance visibility and access to U.S. investors
- Trading to commence on March 6, 2025
TORONTO, March 06, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“Conavi Medical” or the “Company”), a commercial stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures, today announced that its common shares have been approved for uplisting from the OTC Pink Open Market to the OTCQB Venture Market, with trading set to commence on March 6, 2025. The ticker symbol will remain CNVIF, and no action is needed by shareholders. Trading on the OTCQB is expected to complement the Company's existing listing on the TSX Venture Exchange.
“As we move toward commercial launch of our next-generation Novasight system, we’re pleased to increase investor transparency and visibility with this uplisting,” said Thomas Looby, Conavi Medical’s CEO. “We believe this step will increase our exposure to the U.S. investment community and broaden our investor base.”
Operated by the OTC Markets Group, the OTCQB Venture Market is a U.S. trading platform designed for developing and entrepreneurial-stage companies. The Securities and Exchange Commission considers the OTCQB to be an “established public market” for determining the public market price when registering securities for resale. Companies listed on the OTCQB are current in their reporting and undergo an annual verification and management certification process. Additional information about the OTC Markets Group Inc. and the OTCQB can be found at otcmarkets.com.
About Conavi Medical
Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China’s National Medical Products Administration, and Japan’s Ministry of Health, Labor and Welfare. For more information, visit conavi.com.
Cautionary Statement Regarding Forward-Looking Information
This news release contains “forward-looking statements” within the meaning of applicable Canadian and U.S. securities laws, which reflect the current expectations of management of Conavi’s future growth, results of operations, performance and business prospects and opportunities. Forward-looking statements are frequently, but not always, identified by words such as “may”, “would”, “could”, “will”, “anticipate”, “believe”, “plan”, “expect”, “intend”, “estimate”, “potential for” and similar expressions, although these words may not be present in all forward-looking statements. Forward-looking statements that appear in this release may include, without limitation, references to Conavi’s plans for the commercialization of its Novasight Hybrid™ System.
These forward-looking statements reflect management’s current beliefs with respect to future events, and are based on information currently available to management that, while considered reasonable by management as of the date on which the statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies which could result in actions, events, conditions, results, performance or achievements to be materially different from those projected in the forward-looking statements. Forward-looking statements involve significant risks, uncertainties and assumptions and many factors could cause Conavi’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Such factors and assumptions include, but are not limited to, Conavi’s ability to retain key personnel; its ability to execute on its business plans and strategies; and other factors listed in the “Risk Factors” sections of the joint information circular of Conavi dated August 30, 2024 and of the Preliminary Prospectus of the Company dated January 29, 2025 (each of which may be viewed at sedarplus.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully, and prospective investors should not place undue reliance on the forward-looking statements.
Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions and Conavi has attempted to identify important factors that could cause actual actions, events, conditions, results, performance or achievements to differ materially from those described in forward-looking statements, Conavi cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Conavi expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. Accordingly, investors should not place undue reliance on forward-looking statements. All the forward-looking statements are expressly
qualified by the foregoing cautionary statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Contacts
Stefano Picone
Chief Financial Officer
ir@conavi.com
(416) 483-0100
FAQ
When will Conavi Medical (CNVIF) begin trading on the OTCQB Venture Market?
What are the benefits of Conavi Medical's uplisting to OTCQB for investors?
What product is Conavi Medical (CNVIF) preparing to launch?
What requirements must Conavi Medical meet to maintain OTCQB listing?
